CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ImnovAth aims to develop a novel treatment for atherosclerosis by targeting a specific metabolite and its receptor. This approach seeks to enhance the effectiveness of existing therapies and advance towards clinical trials, ultimately leading to a marketable product that addresses cardiovascular disease more effectivel…
Atherosclerosis (AT) is one of the main causes of death worldwide.
Current treatments (e.g. lipid-lowering therapies) are still insufficient to tackle future CV events and we urgently need new complementary treatments to improve therapeutic efficacy.
ImnovAth aims to develop the new idea of targeting a metabolite/metabolite receptor axis to complete our preclinical results with an existing pharmacological agent that blocks this pathway, with the long-term goal of moving towards clinical trials a…
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
